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The tumorigenicity of cancer cells is highly influenced by the extracellular
matrix (ECM) through mechanisms that are poorly understood. Here it is
reported that a variety of 3D ECM microenvironments strongly induce
expression of Id1 and Id3 in melanoma cells. Genetic ablation of Id1/Id3
impairs melanoma cell outgrowth in 3D Matrigel culture and inhibits
melanoma initiation in vivo. Mechanistically, 3D ECM microenvironments
hinder diffusion of endogenously produced bone morphogenetic proteins,
thereby fostering autocrine signaling and Id1/Id3 expression. A compound
screen identifies new coumarin derivatives that potently inhibit both Id1/Id3
expression and melanoma initiation in vivo. Together, the findings reveal a
novel mechanism through which the ECM increases tumorigenicity, identify
Id1/Id3 as melanoma-relevant therapeutic targets, and characterize inhibitors
of Id1/Id3 expression with therapeutic potential.
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1. Introduction
Phenotypic plasticity is thought to en-
able a subpopulation of tumor cells to
support the initiation, long-term mainte-
nance and therapy resistance of tumors.[1]
Plasticity can be acquired by tumor cells
through exposure to appropriate environ-
mental signals.[2] The extracellular matrix
(ECM) within the tumor microenviron-
ment, a complex and dynamic network of
secreted proteins and polysaccharides that
includes collagens, laminins, proteoglycans
and hyaluronic acid,[3] is thought to provide
such signals through its biochemical and
physical properties.[4–6] In mice, the effi-
ciency of tumor initiation increases with the
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severity of immunodeficiency, and through co-injection of tumor
cells with Matrigel, a basement membrane-like mixture of ECM
components.[7] These observations underscore the critical role
that the tumor microenvironment, and in particular the ECM
plays in regulating the tumorigenicity of cancer cells.
Malignant melanoma is the most lethal form of skin cancer.
Although targeted therapy and immunotherapy are improving
patient survival, the management of patients with metastatic dis-
ease remains a major challenge in the clinic, for example due
to lack of response or the acquisition of resistance mutations
during immunotherapy.[8–10] Melanoma cells exhibit a particu-
larly high degree of plasticity that is thought to be due at least
in part to their sensitivity to microenvironmental changes.[11–14]
Notably, the composition of the extracellular matrix surrounding
melanoma cells regulates tumor cell plasticity.[7,15] These obser-
vations suggest that targeting ECM-induced tumorigenesis may
represent a novel approach to melanoma therapy. However, the
mechanisms through which the ECM impacts on the tumori-
genicity of melanoma cells remains to be determined.
Inhibitor of DNA binding 1 and 3 (Id1 and Id3) are transcrip-
tional regulators whose expression is regulated by bone morpho-
genetic protein (BMP) and transforming growth factor 𝛽 (TGF-𝛽)
signaling.[16,17] They act as dominant negative inhibitors of basic
helix-loop-helix (bHLH) transcription factors, by heterodimeriz-
ing with them and preventing them from binding to DNA.[18] Ex-
pression of Id1 and Id3 has been implicated in tumor initiation
and metastatic growth.[19–21] Accordingly, their expression corre-
lates with poor prognosis for many types of cancer,[22] including
melanoma.[23] Loss of Id3 results in an impaired B-cell prolifera-
tion that can be rescued by ectopic overexpression of Id1,[24] in-
dicating functional redundancy between Id1 and Id3.
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Table 1. Co-injection of melanoma cells with ECM components into syn-
geneic mice enhances tumor initiation. Different numbers of melanoma
cells (B16-F10, Ret) were injected into syngeneic mice together with PBS,
Matrigel (10mgmL−1), laminin I (4.5mgmL−1), collagen I (3.4mgmL−1)
or fibronectin (625 µgmL−1) to calculate the tumor initiating cell (TIC) fre-
quency in vivo. The number of animals with a tumor> 1000mm3 in size is
indicated for each group. Tumor growth was monitored for 3 months. The
tumor initiating cell (TIC) frequency was calculated using extreme limit-
ing dilution analysis (ELDA) software.[59] p-values refer to the comparison
with the PBS control.
Number of animals with tumors/total number of injected animals
Cell line Injection
with
Number of injected cells TIC
frequency
p-value
5000 500 100 50 10
B16-F10 PBS 6/6 1/10 0/4 0/6 N.D. 1/2158
Matrigel 6/6 6/6 N.D. 11/11 5/5 1/1 <0.001
laminin I N.D. 5/5 6/6 N.D. 4/6 1/9 <0.001
collagen I N.D. N.D. 4/5 N.D. 0/6 1/80 0.055
fibronectin N.D. N.D. 0/6 N.D. 0/6 N.D. 0.441




Ret PBS 2/6 0/6 0/6 1/2800
Matrigel 5/5 9/10 5/5 1/23 <0.001
laminin I 6/6 5/6 6/6 1/23 <0.001
Here we report that a variety of 3D ECM environments in-
duce Id1 and Id3 expression in melanoma cells through matrix-
assisted autocrine BMP signaling. Genetic ablation of Id1 and
Id3 expression suppressed melanoma cell outgrowth and inva-
siveness in 3D ECM, and inhibited melanoma initiation and
growth in vivo. Through synthesizing and screening a custom
targeted chemical library, we identified a novel substance class
that inhibits Id1 and Id3 expression. In proof of principle exper-
iments, one of the most promising of these compounds was in-
vestigated further and found to exert a strong inhibitory effect on
ECM-mediated Id1 and Id3 expression, and to potently suppress
melanoma initiation and growth in experimental animals. These
data suggest that Id1 and Id3 represent promising therapeutic
targets for melanoma, and identify a new class of chemical in-
hibitors of Id1 and Id3 that can serve as lead compounds for drug
development.
2. Results
2.1. Multiple ECM Environments Promote Melanoma Initiation
In Vivo
Co-injection with Matrigel can profoundly increase the ability of
tumor cells to initiate and grow as tumors inmice.[7,25] In severely
immunocompromised mice, a single melanoma cell co-injected
withMatrigel suffices to initiate a tumor.[7] To investigate whether
increased tumor initiation is specific to particular ECM environ-
ments, we co-injected B16-F10melanoma cells together with var-
ious ECM components into immunocompetent syngeneic mice.
Co-injection with Matrigel and laminin I strongly increased the
tumor initiating cell (TIC) frequency (Table 1). The TIC frequency
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Figure 1. Murine melanoma cells exhibit significantly increased Id1 and Id3 expression in 3D ECM environments. A) B16-F10 (left) or Ret (right) cells
were cultured for 72 h in 2D culture or 3D laminin I (4.5 mg mL−1), B) 3D Matrigel (10 mg mL−1) or C) 3D collagen I (4 mg mL−1) culture. Relative Id1
and Id3 mRNA expression were measured via qRT-PCR. Rplp0 served as a housekeeping gene. n = 3. Student’s t-test: *p < 0.05, **p < 0.01, ***p <
0.001. Error bars = SEM. D) Western Blot analysis of Id1 and Id3 protein expression in B16-F10 and Ret cells cultured in 3D laminin I, E) 3D Matrigel
(10 mg mL−1) or F) collagen I (4 mg mL−1) for 72 h, compared to cells cultured in 2D.
also showed a trend toward an increase after co-injection with
collagen type I, but not with fibronectin (Table 1). Similar exper-
iments with Ret melanoma cells confirmed the robust increase
in TIC frequency upon co-injection with Matrigel or laminin I
into syngeneic mice (Table 1). Tumor growth was also increased
when the melanoma cells were co-injected with these ECM com-
ponents (Figure S1A, Supporting Information). Thus, increased
tumorigenicity of melanoma cells is induced by a number of
ECM environments, and is not limited to Matrigel.
2.2. ECM Environments Induce Id1 and Id3 Expression
To identify changes in transcription that underlie the increased
TIC frequency in response to a defined 3D laminin I environ-
ment, we compared transcriptional profiles between B16-F10
and Ret melanoma cells cultured as a monolayer on standard
plastic surfaces (2D), embedded in 3D laminin I (3D Laminin),
or embedded in 3Dmethylcellulose (3DMC) as a control (Figure
S1B, Supporting Information). Strikingly, for both melanoma
cell lines, the most highly upregulated genes in 3D laminin I
culture were Id1, Id3, and Smad6 (Table S1, Supporting Infor-
mation), archetypal TGF-𝛽 and BMP response genes.[16,17] While
Smad6 negatively regulates TGF-𝛽 and BMP signaling,[26,27]
Id1 and Id3 have been implicated in governing the self-renewal
properties of stem cells,[28] and in promoting tumor initiation by
colon and breast cancer cells.[19–21] In further experiments, we
therefore focused on Id1 and Id3 as potential mediators of the
pro-tumorigenic properties of 3D ECM environments.
We first confirmed by real-time PCR that Id1 and Id3 mRNA
expression is strongly upregulated in B16-F10 and Retmelanoma
cells grown in 3D laminin I compared to 2D (Figure 1A). Further-
more, Id1 and Id3 expression was significantly upregulated in 3D
Matrigel and 3D collagen type I at the mRNA level (Figure 1B,C).
Consistently, Id1 and Id3 protein levels were increased in all three
3D ECM environments compared to 2D conditions (Figure 1D–
F). Thus upregulation of Id1 and Id3 is a common feature of ECM
environments that promote tumor initiation.
To determine whether these observations hold true for other
types of cancer, we co-injected 4T1 murine breast cancer cells
withMatrigel into syngeneicmice, and found a strong increase in
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Table 2. Loss of Id1 and Id3 expression significantly reduces tumor initi-
ation in vivo measured at days 28–30. Five or fifty B16-F10 or Ret control
or Id1/Id3 KO cells were co-injected with Matrigel (10 mg mL−1) into syn-
geneic mice. Each group (control or Id1/Id3 KO) consists of 24 animals
(eight animals for each of the three cell clone tested). Tumor initiation
was scored when tumors with a size of more than 1000 mm3 were present
28–30 days after tumor cell injection. The tumor initiating cell (TIC) fre-
quency was calculated using extreme limiting dilution analysis (ELDA)
software.[59].










B16-F10 control 4/24 17/24 1/38 0.0271
Id1/Id3 1/24 11/24 1/85
Ret control 7/24 20/24 1/24 <0.001
Id1/Id3 1/24 7/24 1/142
TIC frequency (Table S2, Supporting Information). Furthermore,
Id1 and Id3 expression was robustly upregulated in 4T1 cells in
response to 3D laminin I, Matrigel and collagen type I culture
(Figure S1C–E, Supporting Information). Thus upregulation of
Id1 and Id3 in response to 3D ECM environments also occurs in
breast cancer cells.
To determine whether exposure to ECM environments results
in a durable increase in tumor initiation capacity in vivo, we cul-
tured B16-F10 and Ret cells for 72 h in 3DMatrigel as before, but
then removed them from the Matrigel and injected them in PBS
into mice. Pre-culturing in Matrigel did not increase tumor initi-
ation in vivo (Table S3, Supporting Information). In other experi-
ments we found that expression of Id1 and Id3mRNA is reduced
to baseline within an hour after removing cells from 3DMatrigel
and replating them on 2D culture (Figure S1F, Supporting In-
formation). These results indicate that both enhanced tumor ini-
tiation and increased Id1 and Id3 expression require persistent
exposure to an inducing 3D ECM environment.
2.3. Id1 and Id3 Promote Tumor Initiation and Growth of
Melanoma Cells In Vivo
Upregulation of Id1 and Id3 could conceivably explain why tu-
mor initiation and growth is increased when melanoma cells are
co-injected with ECM components in vivo. To investigate this hy-
pothesis, we used CRISPR/Cas9 to successfully abrogate Id1 and
Id3 expression in B16-F10 and Ret cells (Figure S2A, Supporting
Information). Abrogation of Id1 or Id3, and particularly their
simultaneous deletion in Ret cells suppressed tumor growth
(Figure S2B, Supporting Information). We therefore continued
with double knockout cells to test the effects of Id1 and Id3 on tu-
mor initiation in vivo by B16-F10 and Ret cells. To this end, either
5 or 50 control or Id1/Id3 knockout cells were co-injected with
Matrigel into each mouse. While all animals injected with 50
cells eventually developed tumors over a 90-day period, ablation
of Id1 and Id3 expression resulted in a significant delay in tu-
mor initiation (Table 2). In addition, significantly reduced tumor
growth rates in vivo were observed in cells with abrogated Id1 and
Id3 (Figure 2A and Figure S2C, Supporting Information). Thus
Id1 and Id3 are functionally required for tumor initiation and
growth by B16-F10 and Ret cells when co-injected with Matrigel
in vivo.
Loss of Id1 and Id3 resulted in a significantly impaired
colony outgrowth in 3D Matrigel for both B16-F10 and Ret
cells (Figure 2B). Furthermore, Ret cells with abrogated Id1/Id3
expression exhibited a significantly less invasive phenotype
(Figure 2B). Importantly, there was no significant reduction
in the proliferation rate of control and Id1/Id3 KO cells in
2D conditions (Figure S2D, Supporting Information). These
data support the notion that elevated Id1 and Id3 expression is
critical for efficient cell growth in 3D ECM environments such
as Matrigel, which is reflected in the reduced tumor initiation
and growth of the Id1/Id3 KO cells co-injected with Matrigel.
2.4. BMP Signaling Induces Id1 and Id3 Expression in 3D ECM
Next, we sought to elucidate why Id1 and Id3 expression is in-
creased in certain 3D ECM environments. As Id1 and Id3 are
induced by BMP and TGF-𝛽 signaling,[16,17] we inhibited these
pathways. Western blot analysis revealed that cells in 3D Ma-
trigel exhibit increased phospho-Smad1 levels, indicative of ac-
tivation of canonical BMP signaling, which was abrogated by
treatment with the BMP type I receptor inhibitor LDN-193189
(LDN)[29] or with recombinant noggin, a naturally occurring BMP
antagonist,[30] but not with the TGF-𝛽 receptor inhibitor SB-
431542 (SB; Figure 3A).[31] Importantly, LDN and noggin treat-
ment of B16 and Ret cells completely blocked the induction of
both Id1 and Id3 in 3D Matrigel, while SB had no or a less pro-
nounced effect on the levels of the two proteins (Figure 3A). Sim-
ilarly, BMP signaling was also required for increased Id1 and Id3
expression in 3D laminin and 3D collagen environments (Figure
S3A,B, Supporting Information). These data establish BMP sig-
naling as being responsible for increased Id1 and Id3 expression
in 3D ECM environments.
2.5. Matrix-Assisted Autocrine BMP Signaling Regulates Id1 and
Id3 Expression in 3D ECM
In 3D ECM, BMPs that activate BMP signaling and induce Id1
and Id3 expression could in principle be derived from the culture
medium, from the ECM preparations, or from the melanoma
cells themselves. The levels of Id1 and Id3 in 3D culture were
the same in standardMatrigel prepared with 10% fetal calf serum
(FCS),Matrigel with 1%FCS or growth factor-reduced (GFR)Ma-
trigel (Figure S3C, Supporting Information). These results sug-
gest that BMPs derived from the culture medium or contained
within the ECM are not responsible for the induction of Id1 and
Id3 expression in 3D Matrigel.
Several ECM proteins have the potential to positively regulate
BMP signaling through interacting with cell surface receptors.[32]
We therefore set out to test whether cell-ECM interactions in 3D
culture directly promote BMP signaling, and thereby increase Id1
and Id3 expression. To this end, we used alginate, which lacks
epitopes to which cell surface receptors can bind[33] and is free
of growth factors. 3D alginate culture strongly induced Id1 and
Id3 expression compared to 2D conditions (Figure 3C). Blocking
BMP signaling also significantly inhibited the induction of Id1
and Id3 expression in 3D alginate (Figure 3C).
Adv. Therap. 2020, 2000065 © 2020 The Authors. Published by Wiley-VCH GmbH2000065 (4 of 17)
www.advancedsciencenews.com www.advtherap.com
Figure 2. Id1 and Id3 promote melanoma growth. A) Simultaneous Id1 and Id3 gene ablation by CRISPR/Cas9 significantly impairs tumor growth of
melanoma cells in vivo. Fifty control or Id1/Id3 KO cells were co-injected with Matrigel (10 mg mL−1) into syngeneic mice. Each group (24 animals per
group) consisted of three subgroups of 8 animals each, into which each of the individual clones was transplanted. Nested ANOVA: *p < 0.05; ***p <
0.001. Error bars = SEM. B) Loss of Id1/Id3 expression inhibits the outgrowth and invasion of melanoma cells in 3D Matrigel. B16-F10 or Ret control or
Id1/Id3 KO cells were seeded in 3D Matrigel (10 mg mL−1) and incubated for 6 days. Images show control (upper row) and CRISPR/Cas9 cells (lower
row) in the 3D culture. Scale bars = 500 µm. Quantification of colony size and invasion index was performed using Fiji image analysis software.[82]
Mann–Whitney test: ***p < 0.001. Error bars = SD.
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Figure 3. BMP signaling regulates Id1 and Id3 expression in 3D ECM environments. A) Canonical BMP signaling regulates Id1 and Id3 expression.
B16-F10 or Ret cells were incubated in 3D Matrigel or standard 2D conditions. Cells cultured in 3D Matrigel were treated at the start of the culture with
a single dose of recombinant noggin (300 ng mL−1), LDN-193189 (0.5 × 10−6 m) or SB-431542 (10 × 10−6 m). Id1, Id3, Smad1, phoshpo-Smad1 and
Vinculin levels were evaluated by Western blotting. B) Increased Id1 and Id3 expression in murine melanoma cells in 3D alginate. B16-F10 or Ret cells
were cultured for 72 h in 0.75% alginate. To block BMP signaling, cells were incubated with LDN-193189 (0.5 × 10−6 m). Id1 and Id3 mRNA expression
was compared to 2D cultured cells. n = 3. * compared to 2D; # compared to 3D. One-way ANOVA with Tukey’s multiple comparisons test: **/##p <
0.01, ***/###p < 0.001 Error bars = SEM.
The results presented above indicate that neither exogenous
growth factors nor cell-matrix interactions are required for
upregulated Id1 and Id3 expression in 3D microenvironments,
suggesting that melanoma cells themselves may be the source
of BMPs that upregulate Id1 and Id3 in 3D ECM. Noggin,
which blocks ECM-induced Id1 and Id3 expression (Figure 3A),
is an antagonist of BMP2, BMP4, and BMP7,[30] suggesting
that melanoma cell-derived BMP2, BMP4, or BMP7 might be
responsible for the increased Id1 and Id3 expression in 3D ECM
environments. B16-F10 and Ret cells both express BMP4 and
BMP7 but not BMP2 at the mRNA level (Figure 4A). Transcripts
for other BMP ligands could not be detected (data not shown;
list of primers in Table S5, Supporting Information). BMP4 and
BMP7 proteins were both found in conditioned medium from
B16-F10 and Ret cells cultured in 2D conditions (Figure 4B).
The sensitivity of available ELISA assays was too low to quantify
BMP4 in the conditioned medium. Quantification of BMP7 in
the conditioned medium showed that both cell lines secrete
low levels of BMP7 (B16-F10: 14.25 pg mL−1; Ret: 3.9 pg mL−1)
(Figure 4C). These concentrations are insufficient to induce au-
tocrine expression of Id1 and Id3 under 2D culture conditions,
as around 10 ng mL−1 of BMP4 and/or BMP7 are required for
induction of Id1 and Id3 expression (Figure 4D,E). ECM does not
induce BMP4 or BMP7 expression, as no increased expression
was observed in cells cultivated in 3D laminin compared to 2D
culture (Figure S3D, Supporting Information). Furthermore, we
also did not detect consistent upregulation of BMP receptors in
3D Matrigel compared to 2D that could explain increased BMP
signaling in 3D conditions (Figure S3E, Supporting Informa-
tion). In summary, we conclude that B16-F10 andRet cells secrete
low levels of BMP4 and BMP7 that are insufficient to induce
autocrine Id1 and Id3 expression under 2D culture conditions.
We reasoned that 3D ECM may have an impact on the diffu-
sion of BMPs, leading to an increased pericellular accumulation
of BMPs secreted by cells within the ECM. The resulting locally
increased BMP concentrations at the cell surface may thereby be-
come sufficient to induce autocrine BMP-mediated Id1 and Id3
expression. To test this hypothesis, we measured the diffusion
coefficient of fluorescently labeled BMP2 in medium, Matrigel
or laminin using fluorescence correlation spectroscopy (FCS).
The data for BMP2 in medium could be fitted using a simple
model for free 3D diffusion of a single fast diffusing species. For
both laminin andMatrigel, an additional slowly diffusing species
was needed in the fitting to account for the data obtained (Figure
S4A–D, Supporting Information). For the fast diffusing species
of BMP2 in laminin and Matrigel, similar diffusion coefficients
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to bulk medium were obtained (Figure 4F). The slowly diffus-
ing species, which is indicative of transient interactions between
BMP2 and the 3D ECM gels tested, showed diffusion coefficients
of 3.9 ± 0.5 and 0.25 ± 0.03 µm² s−1 for laminin and Matrigel, re-
spectively (Figure 4F). The fraction of slowly diffusing BMP2 was
similar for both gels. By contrast, medium supplemented with
bovine serum albumin (BSA) at a protein concentration equal to
that in 3D Matrigel did not significantly influence the diffusion
of BMP2. Therefore, both Matrigel and laminin strongly reduced
the diffusion coefficient of BMP2 in the case of the slow species
by around 385-fold and 24-fold, respectively, compared to bulk
medium (Figure 4F). These data are consistent with the notion
that ECM environments can act as barriers that inhibit the diffu-
sion of secreted BMP ligands.
Reduced diffusion would predict that BMP accumulates
around cells in 3D Matrigel. To visualize such an accumulation,
we performed an immunofluorescence staining for BMP4 in 3D
Matrigel-embeddedmelanoma cells. Consistent with the strongly
reduced diffusion of BMP in 3D ECM measured by FCS, we ob-
served a strong pericellular accumulation of BMP4 (Figure 4G).
Together, these data are consistent with the notion that endoge-
nously produced BMP4 accumulates around cells grown in 3D
ECM due to decreased diffusion. This leads to increased pericel-
lular BMP concentrations that stimulate Id1 and Id3 expression,
a mechanism we have termed matrix-assisted autocrine signal-
ing (Figure 4H).
2.6. Correlation of ID1/ID3 Expression with ECM Genes and
Invasive Properties in Human Melanoma
To gain insight into the relevance of our findings in murine
melanoma cells to human melanoma samples, we first ana-
lyzed the skin melanoma cohort of The Cancer Genome Atlas
(TCGA). We observed that the expression levels of ID1 and ID3
were very strongly correlated in human melanomas and that
the majority of the tumors (54.7%) expressed higher levels of
ID1 and/or ID3 than normal skin (Figure 5A). We next com-
piled a list of genes coding for structural ECM components (Ta-
ble S4, Supporting Information) and tested whether the levels
of these genes correlated with those of ID1 and ID3. Intrigu-
ingly, the large majority of ECM genes showed a positive corre-
lation with ID1 and ID3 levels, to a significantly higher extent
that a random set containing an equal number of genes (Fig-
ure 5B). These findings indicate that increased ECM abundance
is associated with upregulation of ID1/ID3 expression in human
melanomas, similarly to the murine system. To further assess
the possible involvement of ID1 and ID3 in human melanoma
progression, we analyzed the expression of both genes in a set
of human melanoma cell lines from the Heuristic Online Phe-
notype Prediction (HOPP) database, which uses gene expres-
sion signatures to classify melanoma cell lines as proliferative
or invasive.[34] The expression of both ID1 and ID3 was signifi-
cantly higher in invasive melanoma cells, which have been asso-
ciated with an increasedmetastatic potential[35] and greater resis-
tance to RAF/MEK inhibitors,[36] the standard of care for a large
fraction of melanoma patients. Consistent with other published
findings,[23] these data suggest that ID1 and ID3 expression in
human melanoma is linked to disease progression and therapy
resistance.
2.7. A Targeted Compound Screen Identifies Novel Id1/Id3
Inhibitors
Genetic ablation of Id1 and Id3 expression had a potent inhibitory
effect on tumor initiation and growth in vivo, which, together
with the data in humanmelanomas, suggests that these proteins
are possible therapeutic targets. We therefore set out to identify
novel inhibitors that target Id1 and Id3. As cannabidiol (CBD), a
nonpsychotic cannabinoid, has been reported to partially inhibit
Id1 expression,[37] we synthesized a unique library containing 62
novel coumarin derivatives that are loosely structurally related to
CBD (Data S1, Supporting Information). This library was then
screened for compounds that inhibit Id1 and Id3 expression,
using CBD as a reference substance. To this end, B16-F10 and
Ret melanoma cells were treated with BMP4 (to induce Id1 and
Id3 expression) together with each of the compounds individu-
ally. The ability of the compounds to inhibit Id1 and Id3 protein
expression relative to CBD was assessed using Western blotting
Figure 4. Matrix-assisted autocrine BMP signaling. A) Melanoma cells express BMP4 and BMP7. mRNA expression of BMP2, BMP4 and BMP7 was
analyzed in B16-F10 and Ret cells, as well as the murine breast cancer cell line 4T1, by standard PCR of cDNA on a 3% agarose gel. Positive controls
were derived from B16-F10 cells transfected with expression plasmids for BMP2, BMP4 and BMP7. Predicted amplicon sizes: BMP2: 154 bp, BMP4:
142 bp, BMP7: 122 bp. B) B16-F10 and Ret cells secrete BMP4 and BMP7. Western blot analysis of conditioned medium detects BMP4 and BMP7 after
48 h in OptiMEM. An OptiMEM medium control lacks a specific band. C) Melanoma cells secrete low levels of BMP7. Supernatants of B16-F10 and
Ret cells in 2D culture were analyzed for BMP7 protein levels by ELISA (n = 2). D) B16-F10 or Ret cells were serum-starved overnight and treated with
increasing concentrations of recombinant BMP4 (1, 10, and 100 ng mL−1; 120-05ET, Peprotech) for 1 h prior to RNA isolation. Relative Id1 and Id3
mRNA expression was determined by qRT-PCR. n = 3. One-way ANOVA with Dunnett’s multiple comparisons test: **p < 0.01, ***p < 0.001 compared
to untreated cells. Error bars = SEM. E) B16-F10 or Ret cells were serum-starved overnight and treated with increasing concentrations of recombinant
BMP7 (1, 10, and 100 ng mL−1; 120-03P, Peprotech) for 1 h prior to RNA isolation. Relative Id1 and Id3 mRNA expression was determined by qRT-
PCR. n = 3. One-way ANOVA with Dunnett’s multiple comparisons test: **p < 0.01, ***p < 0.001 compared to untreated cells. Error bars = SEM.
F) The diffusion coefficient of BMP2 is strongly reduced in 3D ECM environments. Upper left: Normalized averaged cross-correlation functions for
BMP2 diffusion in different environments. Upper right: Table showing the results from fitting the obtained correlation functions (left) with a one- or
two-component model for unhindered 3D diffusion. The mean±SEM and the number of measurements per condition (#) is indicated. Lower row:
Distribution of individual parameters obtained from fits under the respective conditions. Black horizontal lines indicate means, boxed regions indicates
error (SEM). A one-component model was sufficient to fit data from measurements in RPMI and RPMI supplemented with BSA. G) Endogenous BMP4
is concentrated pericellularly in 3D Matrigel. B16-F10 cells were cultured in 3D Matrigel and fixed after 72 h. Cryosections were stained for BMP4 and
fluorescence signal detected by a secondary antibody was compared against an isotype antibody control. H) Schematic overview of the mechanism of
matrix-assisted BMP signaling in 3D ECM. BMP diffusion is inhibited by ECM components, which leads to increased pericellular concentrations of BMPs
that are sufficient to induce autocrine signaling, resulting in the induction of the target genes Id1 and Id3.
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Figure 5. The expression of ID1 and ID3 is linked to increased levels of ECM genes and an invasive phenotype in human melanoma. A) ID1 and ID3
expression is strongly correlated in humanmelanomas. Expression (normalized RNA-seq reads), of ID1 and ID3 in samples of the cutaneous melanoma
cohort of The Cancer Genome Atlas (TCGA). A total of 472 tumor samples were analyzed. The red square indicates expression in normal skin. The
percentages indicated on the plot refer to the fractions of tumor samples, which have higher or lower expression of ID1 and/or ID3 than normal skin.
r, Pearson correlation coefficient. B) The expression of ID1 and ID3 correlates with the expression of ECM genes in human melanoma. The expression
of 100 genes coding for structural components of the ECM (Table S4, Supporting Information) was correlated to the expression of ID1 (left panel) and
ID3 (right panel) in the TCGA cutaneous melanoma cohort and the Pearson correlation coefficients were plotted. As a control the correlation of ID1 and
ID3 with a set of 100 random genes is shown. Student’s t-test: ***p < 0.001. Error bars = SEM. C) Increased ID1 and ID3 levels are associated with an
invasive phenotype in human melanoma cells. Expression of ID1 and ID3 in human melanoma cell lines with a proliferative and invasive phenotypes,
as classified using the Heuristic Online Phenotype Prediction (HOPP) algorithm. Expression was analyzed in 101 proliferative cell lines and 90 invasive
cell lines. Student’s t-test: **p < 0.01, ***p < 0.001. Error bars = SEM.
analysis. Around one third of the compounds had an inhibitory
effect on both Id1 and Id3 protein expression (20 out of 62). The
screen identified a compound class defined by eight coumarin
derivatives that inhibited Id1/Id3 protein expression more
potently than CBD (Figure 6A,B). Of these compounds, the com-
pound X6632 strongly inhibited BMP4-induced Id1/Id3 expres-
sion at a concentration of 10 × 10−6 m (Figure S5A,B, Supporting
Information), and potently suppressed 3D ECM-mediated
Id1/Id3 expression in cells cultured in 3D Matrigel (Figure 6C).
2.8. The Coumarin Derivative X6632 Strongly Inhibits Melanoma
Growth In Vivo
To investigate whether X6632 can inhibit tumor initiation and
growth in vivo similarly to genetic ablation of Id1/Id3, B16-
F10 or Ret melanoma cells were injected subcutaneously into
mice. The mice were treated for the first two weeks follow-
ing implantation of the melanoma cells with either DMSO as
a solvent control, with CBD as a reference compound, or with
X6632. Melanoma initiation and growth was then assessed over a
period of 90 days. Treatment with CBD led to a slight reduction
in tumor growth rates and no improvement in tumor-free sur-
vival (Figure 6D,E). By contrast, treatment with X6632 strongly
inhibited tumor growth, significantly delayed tumor initiation,
and even prevented the formation of any tumors in the majority
of mice implanted with B16-F10 cells (Figure 5D,E). Importantly,
treatment of mice with X6632 was well tolerated, and no signs
of toxicity were observed, whereas CBD-treated mice exhibited
treatment-related intestinal injury that became obvious in post-
mortem examination. Together, these results demonstrate that
X6632 is a novel inhibitor of Id1 and Id3 expression, which shows
considerable promise as a lead compound for the development of
new anti-cancer therapies.
3. Discussion
Here we report that 3D ECM can induce BMP-dependent up-
regulation of Id1 and Id3 in melanoma cells through the novel
mechanism of matrix-assisted autocrine signaling. Genetic
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Figure 6. A sub-class of coumarin derivatives exhibits coordinate Id1/Id3 inhibitory activity that is superior to CBD. A) A sub-class of coumarin-type
compounds that inhibit Id1 and Id3 expression. B) Eight coumarin compounds of a common sub-class potently inhibit Id1 and Id3 protein expression.
B16-F10 and Ret cells were treated with BMP4 (to induce Id1 and Id3 expression) together with the indicated compounds at a concentration of 10 ×
10−6 m. DMSO served as a solvent control, CBD served as the reference inhibitor. C) X6632 inhibits 3D ECM-mediated Id1/Id3 expression in melanoma
cells cultured in 3DMatrigel. Cells were cultured in 3DMatrigel (5 mg mL−1) for 72 h and treated at the indicated time points with 10 × 10−6 m of X6632
before lysis. D) X6632 significantly inhibits tumor growth in vivo. Fifty B16-F10 or Ret cells were co-injected with Matrigel (10 mg mL−1) into syngeneic
mice. Significantly reduced tumor growth was observed in X6632 but not CBD treated mice. Data shows tumor volume at the point when the first animal
had to be sacrificed in the DMSO group due to tumors reaching the legal size limit. n = 6–8. ANOVA with Fisher’s least significant difference test: *p
≤ 0.05 compared to DMSO. Error bars = SEM. E) X6632 significantly inhibits tumor initiation in vivo. Fifty B16-F10 or Ret cells were co-injected with
Matrigel (10 mg mL−1) into syngeneic mice. The percentage of tumor-free mice (tumor volume less than 1000 mm3) was analyzed over 90 days. n =
6–8. * compared to DMSO, # compared to CBD. Log-rank (Mantel-Cox) test: */#p < 0.05, ***p < 0.001 Error bars = SEM. In panels (D,E) 2 animals
injected with Ret cells and treated with CBD died during drug treatment and were excluded from the analyses.
deletion of Id1 and Id3 expression in melanoma cells severely
impaired their ability to initiate and sustain tumor growth in
experimental animals. In a chemical library screen, we iden-
tified a novel substance class that concomitantly inhibits Id1
and Id3 protein expression, which exerted potent anti-cancer
activity, while exhibiting no obvious toxicity. These data provide
a proof of principle that Id1 and Id3 represent relevant targets
in melanoma, and identify promising novel compounds with
therapeutic potential that target Id1 and Id3.
BMP signaling is highly susceptible to extracellular regulation
through the biochemical and physical properties of the ECM.[32]
Here we introduce matrix-assisted autocrine signaling as an
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additional mechanism through which the ECM can foster BMP
signaling by suppressing diffusion of endogenously produced
ligand. The diffusion coefficients we measured for BMP2 are
similar to those reported for the Drosophila BMP homolog Dpp
in vivo, where the diffusion coefficient of GFP-tagged Dpp in the
wing imaginal disc was reported as 0.10 ± 0.05 µm2 s−1.[38] This
is comparable to the diffusion coefficient of the slow species we
observed for labelled BMP2 inMatrigel (0.25± 0.03 µm2 s−1), and
suggests that transient interactions with ECM components also
reduce BMP mobility in vivo. The obtained diffusion coefficient
of 96.3 ± 0.9 µm² s−1 for BMP2 in bulk medium is in good agree-
ment with published diffusion coefficients of proteins with sim-
ilar size and under comparable conditions.[39]
Matrix-assisted autocrine signaling could conceivably not only
foster BMP signaling, but may also be operative in any situation
where cells express receptors for particular growth factors or
cytokines, but produce only low levels of the cognate ligands that
do not normally suffice to trigger the receptor in an autocrine
manner. If a particular ECM environment substantially inhibits
free diffusion of the ligand, then increased pericellular levels of
the ligand could develop that ultimately reach the concentration
required to activate the receptor, triggering autocrine stimulation.
Our data support the notion that matrix-assisted autocrine sig-
naling fosters BMP-induced expression of Id1 and Id3, leading
to increased tumorigenicity of melanoma cells. In the model
systems analyzed, BMP4 and BMP7 were expressed at low lev-
els by the melanoma cells, and were implicated in mediat-
ing the matrix-assisted autocrine signaling. For example nog-
gin, which has the strongest binding affinity for BMP2, BMP4,
and BMP7,[30,40] suppressed matrix-induced Id1 and Id3 expres-
sion. These data therefore suggest that BMP4 and BMP7 may
be instrumental in determining tumorigenicity in melanoma
cells. Consistent with this notion, BMP4 and BMP7 expres-
sion is upregulated in melanoma compared to nevi,[41] and
BMP7 expression correlates withmore aggressivemelanoma cell
phenotypes.[41,42]
Increased Id1 and Id3 expression may be relevant not only in
the context of melanoma initiation, but also during invasion and
metastasis. Notably, culture in 3D Matrigel increased outgrowth
and invasiveness of melanoma cells in an Id1/Id3-dependent
manner. Consistently, Id1 has been reported to be upregulated
in metastatic melanoma.[23] Furthermore, while other tumors of-
ten respond with inhibition of migration or invasion to BMP
treatment,[43–45] melanoma cells generally show enhanced mi-
gration and invasion following BMP stimulation.[41,46,47] More-
over, BMP ligands are more highly expressed in advanced
stage melanomas, and are often secreted by melanoma cells
themselves.[41,46] Thus during metastasis, the ECM constituents
that disseminated tumor cells encounter when intravasating into
a new organ microenvironment may be decisive in supporting
tumor cells, for example through matrix-assisted autocrine BMP
signaling, allowing the cells to survive and form metastases.
We also observed here that breast cancer cells increase Id1
and Id3 expression in 3D ECM environments. This suggests that
therapeutic targeting of Id1 and Id3, which is upregulated in the
cancer context through either matrix-assisted autocrine regula-
tion or through other mechanisms, may be more broadly ap-
plicable across different tumor types. Cancer entities reported
to exhibit increased Id1 and/or Id3 levels that correlate with
poor survival include prostate cancer,[48] B-acute lymphoblastic
leukemia,[49] non-small cell lung cancer,[50] ovarian cancer,[51]
esophageal squamous cell carcinoma,[52] and breast cancer.[53]
In many cases, Id1 and Id3 are co-expressed in tumor tissues.
Given the evidence that Id1 and Id3 can compensate for each
other,[24] their simultaneous targeting is likely to be beneficial,
as suggested by the more robust reduction of tumor growth
seen with the Id1/Id3 double knockout cells, compared to Id1
or Id3 single knockouts. Furthermore, as Id1 and Id3 are up-
regulated in response to vemurafenib, and mediate adaptive re-
sistance in melanoma cells to vemurafenib treatment,[54] target-
ing Id1 and Id3 may prevent melanoma cells from developing
adaptive resistance. The elevated BMP2 transcription observed
in melanoma patients treated with BRAF or MEK inhibitors[46]
could also potentially result in elevated expression of the BMP2
target genes Id1 or Id3. Indeed, we detected markedly higher
levels of ID1 and ID3 expression in human melanoma lines
with an invasive phenotype, which has been shown to be more
resistant to RAF/MEK inhibitors.[36] These observations sug-
gest that combining inhibitors of Id1 and Id3 with BRAF or
MEK inhibitors in melanoma treatment may provide benefit for
patients.
While the expression of Id1 and Id3 is not limited to tumor
tissue, the fact that their loss potently suppressed tumor growth
can offer a therapeutic window for their inhibition as cancer drug
targets. Indeed, while the X6632 compound had a strong effect
on tumor growth, we did not observe any adverse side effects
from the treatment. The lack of in vivo toxicitymay reflect the fact
that although Id1 and Id3 proteins play a role in regulating the
self-renewal and pluripotency of adult stem cells, they are mostly
required in this context in response to injury.[55,56] It should also
be noted that apart from the direct impact of Id1/Id3 targeting on
tumor cells, the inhibition of Id1/Id3 in non-neoplastic tissues
may actually augment the anti-cancer effects through regulating
the tumor microenvironment. Id1 and Id3 have been implicated
in the induction of angiogenesis,[57] lymphangiogenesis,[58] and
in determining the differentiation status of tumor-promoting im-
mune components such as myeloid-derived suppressor cells[59]
and Foxp3+ Treg cells.
[60] Inhibition of Id1 and Id3 may therefore
suppress tumor growth and progression not only by direct effects
on tumor cells, but also through preventing the creation of a pro-
tumorigenic microenvironment.
A number of tools have been developed for inhibiting Id1 or
Id3 expression experimentally. Peptide-based approaches have
been used, but difficulties in delivering the molecule to target
cells and the pharmacological properties of the substances limit
their efficacy.[61,62] Small molecule inhibitors and natural prod-
ucts that target Id1 or Id3 have also been described, but are rather
unspecific.[63,64] CBD partially inhibits Id1 expression at the tran-
scriptional level[37] and has anti-cancer properties,[65–67] but reg-
ulates the expression of other genes apart from Id1.[68,69] In com-
parison to these approaches, the novel inhibitors of Id1 and Id3
we report here offer considerable potential therapeutic advan-
tages, both in terms of potency, anti-cancer efficacy, concomitant
dual inhibition of Id1 and Id3, and lack of observable side effects.
Future work will focus on investigating the therapeutic potential
of these compounds.
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4. Conclusion
Our study demonstrates that particular ECM environments can
increase tumor initiation and growth through matrix-assisted
autocrine BMP signaling, which upregulates expression of the
transcriptional regulators Id1 and Id3. Id1 and Id3 are key me-
diators of matrix-regulated tumorigenesis, as their ablation in
melanoma cells led to decreased growth and invasion in 3D ma-
trix environments, and strongly impaired tumorigenesis in ani-
mal melanomamodels. Importantly, this study identified a novel
class of coumarin derivatives that inhibit Id1 and Id3 expression
and suppress melanoma initiation and growth in vivo. These
compounds represent promising leads for anti-cancer drug de-
velopment.
5. Experimental Section
Cell Lines: The murine melanoma cell lines B16-F10 [70] and Ret [71]
were cultured in DMEM or RPMI medium containing 10% FCS, 1% peni-
cillin/streptomycin, respectively. Themurine breast cancer cell line 4T1 [72]
was cultured in DMEM containing 10% FCS, 1% penicillin/streptomycin.
Cells were incubated at 37 °C and 5%CO2 atmaximal humidity in a cell cul-
ture incubator. 3D cultures were incubated in low-attachment poly-HEMA
coated wells. Cells were regularly tested for mycoplasma infection using
the VenorGeMMycoplasma PCRDetection Kit (11-1250, Minerva Biolabs)
Collagen I Isolation from Mouse and Rat Tails: Mouse or rat tails were
briefly rinsed with 70% EtOH, skin was removed and collagen fibers were
cut into pieces and collected in PBS. After removing residual blood ves-
sels, cartilage and muscle, collagen fibers were air dried and dissolved in
0.1% acetic acid at 4 °C, filtered through glass wool, then lyophilized and
redissolved at an appropriate concentration in 0.1% acetic acid.
3D Cell Culture: For 3D cultures, cells were embedded in Matrigel
HC (5 mg mL−1 or 10 mg mL−1; 354 262, Corning Inc), Matrigel Growth
Factor Reduced (GFR, 5 mg mL−1), laminin I (4.5 mg mL−1; 3446-005-
01, Trevigen), collagen type I (4 mg mL−1; isolated from rat/mouse tails,
mixed with HBSS buffer and NaHCO3 (7:1:1 v/v/v) and neutralized with
NaOH), 0.75% alginate (180 947, Sigma Aldrich) in MOPS buffer (10 ×
10−3 m MOPS, 0.85% NaCl, pH 7.2) and subsequently seeded into a poly-
HEMA-coated well. Polymerization of the gels was performed for 30 min
(Matrigel HC, collagen I) or 3 h (laminin I) at 37 °C. Alginate gels were
crosslinked by addition of a polymerization solution (10 × 10−3 m MOPS,
100 × 10−3 m CaCl2, pH 7.2) at room temperature for 5 min. After poly-
merization, gels were carefully overlaid with growth medium. Cells were
cultured for 72 h prior to analysis. The following recombinant proteins
and small molecule inhibitors were used for blocking experiments: recom-
binant noggin (120-10C, Peprotech), LDN-193189 trihydrochloride (1509,
Axon Medchem) and SB-431542 (S1067, SelleckChem).
Tumor Growth and Initiation In Vivo: Mice were kept in groups of 4
in type III macrolon filtertop cages (Tecniplast, Hohenpeißenberg, Ger-
many) containing SAFE fs14 bedding (Rettenmaier & Söhne, Rosenberg,
Germany). Rat/mouse extruded food (SSNIFF, Soest, Germany) and ster-
ilized water acidified with HCl (pH: 2.8–3.1) was provided ad libitum. The
specific-pathogen-free area was kept at 20 °C and 30–60% humidity on
a 7:00–20:00 light cycle. The health status of the animals in the facility
was routinely assessed by a commercial veterinarian laboratory (mfd Diag-
nostics, Wendelsheim, Germany) through serological examinations every
three months (epizootic diarrhoea of infant mice, mouse hepatitis virus,
murine norovirus,minute virus ofmice, Theiler´s encephalomyelitis virus,
Pasteurella pneumotropica) or annually (Clostridium piliforme, Mousepox,
lymphocytic choriomeningitis virus, mouse adenovirus type 1 and type 2,
Mycoplasma pulmonis, pneumonia virus of mice, Reovirus type 3, Sendai
virus). The serology was found to be negative for the parameters tested. In-
house bred C57BL/6J mice aged 8–12 weeks were randomly allocated into
experimental groups. Co-injection experiments with Id1/Id3 KO cells were
performed with equal numbers of female andmalemice in each group. For
compound treatments only female mice were taken into the experiments.
Group sizes were calculated using Fisher´s test (alpha = 5%, power =
80%). Cells were harvested using trypsin/EDTA and washed in PBS. The
indicated numbers of living melanoma cells were subcutaneously injected
into the flank of syngeneic mice in 100 µL PBS. For co-injection experi-
ments, the indicated number of living cells was resuspended in 100 µL
Matrigel HC (10 mg mL−1; BD Biosciences), laminin I (4.5 mg mL−1; Tre-
vigen), collagen I (3.4 mg mL−1) or fibronectin (625 µg mL−1; Biopur),
and subcutaneously injected into the flank of syngeneic mice. Tumor vol-
ume was calculated using the formula 4/3𝜋 (d1/2 × d2/2 × d3/2), where
d1–d3 represents the diameter of the tumor in three dimensions. Tumor
initiating cell (TIC) frequency and p-values were calculated using ELDA
software.[68] For drug treatments, CBD or X6632 were dissolved in DMSO,
then injected intraperitoneally in a volume of 30 µL and at a dose of 18 mg
kg−1 for the first 14 days following injection of the melanoma cells. Ani-
mal experiments were performed according to German legal requirements
and were approved by the local regulatory authorities (approval num-
bers AZ 35–9185.81/G-83/04, AZ 35–9185.81/G-6/10, AZ 35–9185.81/G-
45/16, AZ 35–9185.81/G-301/16).
Microarray Analysis: Gene expression profiles of B16-F10 and Ret
melanoma cells cultured in 3D laminin I were compared to cells cultured
as a monolayers on normal tissue culture plastic (2D), or as spheroids in
methylcellulose-containing medium (3D MC) as previously described.[73]
All conditions were analyzed in biological triplicates. RNA was isolated
using TRIzol (Life technologies) according to the manufacturer’s instruc-
tions. Further RNA processing, microarray analysis, bioinformatic analy-
sis and quality control of the data was performed at Institut Curie, Paris
(Translational Research Department, Affymetrix Platform) using MOE430
2.0 Arrays.
RNA Isolation and qRT-PCR: Cells were harvested for RNA isolation by
directly adding TRIzol (Thermo Fisher Scientific) to the cells monolayer or
cells embedded in 3Dmatrices. RNA was subsequently isolated according
to themanufacturer’s instructions. RNA (1–5 µg) was incubatedwithDNa-
seI (1–5 U; Thermo Fisher Scientific) for 30 min at 37 °C. DNaseI was inac-
tivated by addition of EDTA and incubation at 65 °C for 10 min. cDNA was
synthesized using reverse transcriptase (Thermo Fisher Scientific). Neg-
ative controls lacking reverse transcriptase were prepared for each sam-
ple to confirm successful DNAse treatment. Quantitative RT-PCR (qRT-
PCR) was performed using SYBR Green mix (Applied Biosystems) on the
OneStep Plus Realtime-PCR System (Applied Biosystems) or MX3005P
(Stratagene) for 40 cycles with the following PCR conditions: 15 s 95 °C,
1 min 60 °C, 1 in 72 °C. Data were normalized to Rplp0, and relative ex-
pression of the target genes was determined using the ΔΔCt method. A
list of primers can be found in Table S5 (Supporting Information).
Western Blot: Western blot analysis was performed as previously
described.[74] Proteins in cell culture conditioned medium were concen-
trated using StrataClean Resin beads (Agilent) for 2 h at 4 °C under rota-
tion prior to Western blotting. The following primary antibodies were used
to detect specific proteins: Id1 (195-14, CalBioreagents), Id3 (17-3, Cal-
Bioreagents), phospho-Smad1 (13820S, Cell Signaling), Smad1 (9743S,
Cell Signaling), 𝛽-actin (AC-15, Sigma Aldrich), vinculin (VIN-11-5, Sigma
Aldrich), BMP4 (MAB1049, EMD Millipore) and BMP7 (500-P198, Pepro-
tech). Protein bands were detected using HRP-conjugated secondary an-
tibodies (P0447, P0448, Agilent Technologies) and enhanced chemilumi-
nescence (32 106, Thermo Fisher Scientific).
CRISPR/Cas9: Generation of Id1/Id3 KO clones was performed as
previously reported.[74] In short, cells were co-transfected with a gRNA
vector, hCas9 plasmid[75] and sequence-specific single stranded donor
oligonucleotides using Lipofectamin2000 reagent according to the man-
ufacturer’s protocol. Single cell clones were expanded and screened for
alterations in genomic DNA sequences of the Id1 and Id3 genes with
sequence-specific primers. Colonies with alterations in the genomic DNA
sequences were selected and checked for Id1/Id3 protein expression by
Western blot analysis. Colonies lacking a specific band for the Id1/Id3 pro-
tein were selected, seeded as single cells in 96-wells and subsequently an-
alyzed for genomic alterations and the loss of Id1 and Id3 protein expres-
sion. Single cell clones obtained from the parental cell line were used as
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controls. The sequences of vectors, oligonucleotides and primers used for
CRISPR/Cas9 ablation of the Id1 and Id3 genes are summarized in Table
S6 (Supporting Information).
3D Matrigel Assay: Cells (2 × 103) were mixed with Matrigel to obtain
150 µL of a cell/Matrigel (10 mg mL−1) solution, which was seeded into a
well of a 48-well plate. The gel was allowed to solidify at 37 °C for 30 min
andwas subsequently overlaid with complete growthmedium (500 µL). Af-
ter six days of culture, images were captured using a Leica DMI6000 B mi-
croscope at six different x/y positions in every well, and a minimum of five
horizontal layers (z levels) at each position in order to get every colony in
focus. Image analysis was performed using Fiji software.[76] Colonies were
masked using the wand tool and the perimeter and area for all colonies
with a minimum pixels size of 1500 were measured. An invasion index [77]
was calculated as follows: Invasion index = (perimeter)2/area, resulting in
a dimensionless measure of invasiveness.
Proliferation Assay in 2D: Cells were incubated for 72 h in 96-well plates
and DNA content (as a measure of cell proliferation) was analyzed us-
ing the CyQUANT proliferation assay (C35006, Thermo Fisher Scientific).
Growth medium was removed and 50 µL of CyQUANT dye diluted 1:500
in 1x HBSS was added per well. Plates were incubated for 15 min at
37 °C to allow the CyQUANT dye to incorporate into DNA. Fluorescence
was measured by excitation at 485 nm and detection of emission at
530 nm, at 25 positions in each well using a Tecan Infinite M200 reader.
ELISA: To determine the concentration secreted of BMP4 and BMP7,
melanoma cells were cultured in serum-free medium with 1% peni-
cillin/streptomycin and 2% B27 supplement (Invitrogen, Darmstadt, Ger-
many) for 48 h. The conditioned medium was harvested, centrifuged to
clear cell debris and directly analyzed using the BMP4 (ABIN1371421,
antibodies-online) or BMP7 ELISA Kit (ABIN365657, antibodies-online)
according to the manufacturer’s instructions.
Immunofluorescence Staining and Confocal Microscopy: Cells were cul-
tured in 3D Matrigel (10 mg mL−1) for 72 h. The cell/Matrigel plug was
fixed with 2% PFA / 0.1% glutaraldehyde for 30 min, then washed exten-
sively with 0.1 m glycine in PBS. The plug was transferred to a 50 mL Fal-
con tube with 20% sucrose in PBS and allowed to sink to the bottom of
the tube at 4 °C for 3–4 days. The plug was then embedded in Tissue-Tek
O.C.T. compound and frozen at −80 °C. Cryosections (20 µm) were cut
and air-dried on a glass slide. For immunofluorescence staining, cryosec-
tions were hydrated in PBS for 1 h. Blocking was performed using the
blocking solution supplied with the M.O.M. Kit (BMK-2202, Vector labs)
overnight at 4 °C. The next day, the samples were incubated in antibod-
ies against BMP4 (500-M121, Peprotech) or mouse IgG isotype control
(sc-2025, Santa Cruz) over two nights at 4 °C. After washing with PBS,
secondary antibodies against mouse IgG (#A-11003, Thermo Fisher Sci-
entific) were applied over night at 4 °C. After washing with PBS, slides were
mounted with DAPI Fluoromount-G (0100-20, SouthernBiotech). Confo-
cal microscopy images were obtained using a Leica SP5 MP (LIMA core
facility, Medical Faculty Mannheim, University of Heidelberg). Image anal-
ysis was performed using Fiji.[76]
Fluorescence Correlation Spectroscopy: Recombinant human BMP2
protein (BioVision, Milpitas, USA) was labeled using the Alexa Fluor 555
Microscale Protein Labeling Kit (A30007, Thermo Fisher Scientific) accord-
ing to the manufacturer’s protocol. The degree of labeling was calculated
to be ∼4.5 Alexa555 molecules/BMP2 dimer. The labeled BMP2 was dia-
lyzed using the Slide-A-Lyzer Dialysis cassette with molecular weight cut-
off of 10 kDa (66 380, Thermo Fisher Scientific). The dialyzed BMP2 was
stored at −20 °C with BSA as stabilizer, and protected from light.
BMP2 mobility in Matrigel, laminin, RPMI growth medium and RPMI
supplemented with 10 mg mL−1 bovine serum albumin (Sigma-Aldrich)
was determined by fluorescence correlation spectroscopy using a SP5 con-
focal scanning microscope (Leica) equipped with a 63x water immersion
objective (HCX PL APO CS, Leica) and a pulsed white light laser (SuperK,
Koheras). Time-correlated single photon streams were recorded using
two fiber-coupled avalanche photo diodes (APDs, SPCM AQR-14 Perkin-
Elmer) connected to aHydraharp 300 time-correlated single photon count-
ing (TCSPC) system via a PHR800 router (both PicoQuant) for recording
time-correlated single photon data streams. The white light laser was op-
erated at 80 MHz pulse repetition rate and a wavelength of 540 nm was
selected for excitation of Alexa555. An excitation intensity of 4 µW, well be-
low the saturation intensity of Alexa555, was used for all measurements.
Emitted fluorescence was spectrally filtered with a 585/65 nm bandpass
filter and distributed onto both APDs using a 50/50 beam splitter. Mea-
surements were performed for 180 seconds per data point, at a distance
of 10 µm from the coverslip surface, and at 26 °C.
Samples were prepared in LabTek chambered coverslips (Nunc) using
RPMI (Gibco) to dilute gels and Alexa555-labeled BMP2. Alexa555-labeled
BMP2 (20 × 10−9 m protein), laminin (4.5 mg mL−1) or Matrigel (10 mg
mL−1) were mixed extensively and incubated at 37 °C for at least 1 h. Prior
to measurements, pre-incubated samples were equilibrated at room tem-
perature for at least 30 min before starting data acquisition.
Raw TCSPC data was acquired and correlated using the SymPhoTime
software package (PicoQuant). Correlations were computed as cross-
correlation of the signals recorded by the two APDs for lag times from
0.1 µs to 10 s. Correlated data was fitted with models including one or two
species with free 3D diffusion and a triplet fraction to account for observed
blinking of Alexa555. All fits were performed using PyCorrFit.[78] The effec-
tive observation volume (Veff) of the setup was calibrated using the pub-
lished diffusion coefficient for rhodamine B of 427 µm2 s−1 in aqueous
solution at 25 °C.[79] Typical for Veff were 0.22 fL with a structural parame-
ter (beamwaistz/waistxy) K around 5.5.Measurements were fit individually
with fixed values for triplet time of BMP2-conjugated Alexa555 (3.9 µs de-
termined from an unrestricted fit of BMP2/RPMI data), and structural pa-
rameter (5.5, determined from rhodamine B calibration measurements).
Raw and fitted data was averaged using custom-written routines in Matlab
(MathWorks).
Bioinformatic Analysis: Gene expression data (RNA-Seq V2 RSEM) for
tumor and normal tissue from the cutaneous melanoma cohort of The
Cancer Genome Atlas (TCGA SKCM, Firehose Legacy; 472 samples with
mRNA data), were downloaded from the National Cancer Institute GDC
Data Portal and the cBio Portal.[80,81] The list of genes coding for ECM
structural components (Table S4 (Supporting Information), a total of 100
genes) was assembled based on a survey of the literature and searches
of the NCBI Gene database. A random set of control genes (Table S4,
Supporting Information) was assembled from the first 100 genes along
human chromosome 1, for which mRNA expression data were available
for the TCGA cutaneous melanoma cohort. For analysis of gene expres-
sion in human melanoma cell lines with proliferative and invasive pheno-
types the Melanoma Phenotype-Specific Expression (MPSE) facility of the
Heuristic Online Phenotype Prediction (HOPP) tool[34] was used.
Synthetic Route toward Shown Coumarin Compounds: KHMDS, THF,
dibromo alkane, −16 °C to r.t., 16 h, 78%; b) DIBAL-H, DCM, −78
°C, 1 h, 92%; c) 1) n-propyl triphenyl phosphonium bromide, KHMDS,
THF, 0 °C to 10 °C, 30 min, 2) starting material, 10 °C, 1 h, 99%; d)
Pd/C, H2-atmosphere, ethyl acetate, 24 h, 97%; e) 1.) TMEDA, diethyl
ether, 0 °C, n-BuLi, 2 h, r.t., 2.) 0 °C, DMF, 4 h, r.t., 91%; f) AlCl3, NaI,
ACN, DCM, 1.5 h, r.t., 80%; g) hexanoic acid anhydride, K2CO3, mi-
crowave irradiation (180 °C, 65 min, 300 W), 82%; h) BBr3 in CH2Cl2
(5.00 equiv.), CH2Cl2, −78 °C – rt (30 min), 92% (Figure S5B, Supporting
Information).
Synthesis of Compound X6632—1-(3,5-
Dimethoxyphenyl)cyclohexane-1-carbonitrile: KH-
MDS (25.3 g; 127mmol, 3.00 equiv.) was added to
a solution of 2-(3,5-dimethoxyphenyl)acetonitrile
(7.50 g; 42.3 mmol, 1.00 equiv.) in abs. tetrahy-
drofuran (200 mL) under argon counterflow at
−16 °C. The mixture
was stirred for 3 min at the same temperature and then 1,4-
dibromopentane (6.24 mL; 10.6 g, 46.6 mmol, 1.10 equiv.), diluted in abs.
tetrahydrofuran (50 mL), was added dropwise. The mixture was allowed
to warm to room temperature and stirred overnight. The reaction was
quenched via the addition of ammonium chloride solution (150 mL) and
diluted with 100 mL of diethyl ether. The organic layers were extracted with
diethyl ether (3 × 200 mL) and the combined organic layers were dried
over sodium sulfate. Removal of the volatiles under reduced pressure and
purification via flash column chromatography (CH/EtOAc 5:1) resulted in
8.09 g (78%) of the pure product as a colorless oil. Analytical data are
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consistent with the literature.[82] Rf (CH/EtOAc 5:1): 0.43; 1H NMR
(300MHz, CDCl3): 𝛿 = 6.63 (d, J= 2.2Hz, 2H, 2×HAr), 6.40 (t, J= 2.2Hz,
1H, HAr), 3.81 (s, 6H, 2 ×OCH3), 2.21–2.16 (m, 2H, CH2), 1.93–1.65 (m,
6H, CH2), 1.46–1.02 (m, 2H, CH2) ppm.
Synthesis of Compound X6632—1-(3,5-
Dimethoxyphenyl)cyclohexane-1-carbaldehyde: A
solution of 1-(3,5-dimethoxyphenyl)cyclohexane-
1-carbonitrile (7.97 g; 32.5 mmol, 1.00 equiv.)
in abs. dichloromethane (250 mL) under argon
atmosphere was cooled to −78 °C and DIBAL-H
(81.2 mL; 1 m in dichloromethane, 81.2 mmol,
2.50 equiv.) was added dropwise. The mixture was stirred for an additional
1 h at the same temperature and the reaction was then quenched by drop-
wise addition of 10% aqueous sodium potassium-tartrate (120 mL). Af-
ter thawing up to room temperature the mixture was stirred for another
40 min and the aqueous layer extracted with ethyl acetate (3 × 200 mL).
The combined organic layers were washed with brine (300 mL) and dried
over sodium sulfate. Removal of the volatiles under reduced pressure and
purification via flash column chromatography (CH/EtOAc 10:1) resulted
in 7.39 g (92%) of the pure product as a colorless oil. Analytical data
are consistent with the literature.[83] Rf (CH/EtOAc 20:1): 0.20; 1H NMR
(300 MHz, CDCl3): 𝛿 = 9.34 (s, 1H, CHO), 6.46 (d, J = 2.2 Hz, 2H, 2 ×
HAr), 6.37 (t, J = 2.2 Hz, 1H, HAr), 3.78 (s, 6H, 2 ×OCH3), 2.27–2.22 (m,
2H, CH2), 1.85–1.78 (m, 2H, CH2), 1.69–1.57 (m, 3H, CH2), 1.52–1.25
(m, 3H, CH2) ppm.
Synthesis of Compound X6632—(Z)-1-(1-
(But-1-en-1-yl)cyclohexyl)-3,5-dimethoxybenzene:
KHMDS (18.8 g; 94.3 mmol, 3.00 equiv.) was
added to a suspension of n-propyl triphenylphos-
phoniumbromide (36.3 g; 94.3mmol, 3.00 equiv.)
in abs. tetrahydrofuran (300 mL) at 0 °C, under
argon counterflow. The mixture was stirred for
30 min at 10 °C and a solution of 1-(3,5-dimethoxyphenyl)cyclohexane-
1-carbaldehyde (7.81 g; 33.7 mmol, 1.00 equiv.) in abs. tetrahydrofuran
(50mL) was added dropwise. After stirring for another 60min the reaction
was quenched by the addition of ammonium chloride solution (200 mL).
The aqueous layer was extracted with diethyl ether (3 × 200 mL) and the
combined organic layers were dried over sodium sulfate. Removal of the
volatiles under reduced pressure and purification via flash column chro-
matography (CH/EtOAc 10:1) resulted in 8.62 g (99%) of the pure product
as a colorless oil. Analytical data are consistent with the literature.[83] Rf
(CH/EtOAc 5:1): 0.65. 1HNMR (300MHz, CDCl3): 𝛿 = 6.58 (d, J= 2.3 Hz,
2H, 2×HAr), 6.28 (t, J= 2.3 Hz, 1H, HAr), 5.63 (dt, J= 11.2 Hz, J= 1.7 Hz,
1H, HDB), 5.34 (dt, J = 11.2 Hz, J = 7.4 Hz, 1H, HDB), 3.78 (s, 6H, 2 ×
OCH3), 1.95–1.90 (m, 2H, CH2), 1.72–1.56 (m, 9H, CH2), 1.31–1.24 (m,
1H, CH2), 0.72 (t, J = 7.5 Hz, 3H, CH3) ppm.
Synthesis of Compound X6632—1-(1-
Butylcyclohexyl)-3,5-dimethoxybenzene: Palla-
dium (1.73 g) on activated charcoal (10% Pd/C)
was added to a solution of ((Z)-1-(1-(but-1-en-1-
yl)cyclohexyl)-3,5-dimethoxybenzene (8.50 g) in
ethyl acetate. Hydrogen gas was bubbled through
the solution for several hours and subsequently
kept under hydrogen atmosphere for 24 h. Filtration through Celite, rinsing
with ethyl acetate and removal of the volatiles resulted in 8.31 g (97%) of
the pure product as a colorless oil. Analytical data are consistent with the
literature.[83] Rf (CH/EtOAc 5:1): 0.68. 1H NMR (300 MHz, CDCl3): 𝛿 =
6.48 (d, J = 2.3 Hz, 2H, 2 × HAr), 6.3 (t, J = 2.3 Hz, 1H, HAr), 3.80 (s,
6H, 2 × OCH3), 2.02–1.98 (m, 2H, CH2), 1.57–1.36 (m, 10H, 5 × CH2),
1.18–1.09 (m, 2H, CH2), 0.96–0.88 (m, 2H, CH2), 0.78 (t, J = 7.3 Hz, 3H,
CH3) ppm.
Synthesis of Compound X6632—4-(1-
Butylcyclohexyl)-2,6-dimethoxybenzaldehyde:
1-(1-butylcyclohexyl)-3,5-dimethoxybenzene
(8.26 g; 29.9 mmol, 1.00 equiv.) was dissolved
in diethyl ether (60 mL), and TMEDA (6.72 mL;
5.21 g, 44.8 mmol, 1.50 equiv.) was added
dropwise. The solution was cooled to 0 °C and
n-butyl lithium (17.9 mL; 2.5 m in n-hexanes, 44.8 mmol, 1.50 equiv.)
was added slowly. After stirring for 4 h at room temperature, the solu-
tion was cooled to 0 °C, dimethylformamide (6.89 mL; 6.551 g, 89.7 mmol,
3.00 equiv.) were added and themixture was stirred for another 4 h at room
temperature. The reaction was quenched by the addition of brine (60 mL)
and extracted with diethyl ether (3 × 15 mL). The combined organic layers
were dried over sodium sulfate, the volatiles were removed under reduced
pressure and the residue was then purified via flash column chromatogra-
phy (CH/EtOAc 10:1) to result in 8.31 g (91%) of the product as yellow oil
that was used directly in the next step. Analytical data are consistent with
the literature.[83] Rf (CH/ EtOAc 10:1): 0.19; 1H NMR (300 MHz, CDCl3):
𝛿 = 10.46 (s, 1H, CHO), 6.52 (s, 2H, 2 × HAr), 3.89 (s, 6H, 2 × OCH3),
2.07–1.94 (m, 2H, CH2), 1.66 – 1.33 (m, 10H, 5 × CH2), 1.29–1.04 (m, 2H,
CH2), 1.01–0.85 (m, 2H, CH2), 0.79 (t, J = 7.3 Hz, 3H, CH3) ppm.
Synthesis of Compound X6632—4-(1-
Butylcyclohexyl)-2-hydroxy-6-methoxybenzaldehyde:
4-(1-Butylcyclohexyl)-2,6-dimethoxybenzaldehyde
(8.00 g; 1.00 eq, 26.3 mmol) was dissolved
in a mixture of dry acetonitrile (100 mL) and
dry dichloromethane (50 mL), cooled to 0 °C,
and aluminum trichloride (8.76 g; 65.7 mmol,
2.50 eq,) and sodium iodide (9.85 g; 65.7 mmol, 2.50 eq,) were added
slowly under argon counterflow. The reaction mixture was stirred for
1.5 h at room temperature, quenched with water, and extracted with
dichloromethane (3 × 30 mL). The combined organic layers were then
washed with sodium thiosulfate solution, dried over sodium sulfate and
after removal of volatiles, the crude product was purified via flash column
chromatography (CH/EtOAc 40:1) to result in 6.11 g (80%) of a yellow oil.
Analytical data are consistent with the literature.[83] Rf (CH/EtOAc 40:1):
0.26; 1H NMR (300 MHz, CDCl3): 𝛿 = 11.92 (s, 1H, C2-OH), 10.26 (s, 1H,
CHO), 6.51 (d, J = 1.3 Hz, 1H, HAr), 6.34 (d, J = 1.3 Hz, 1H HAr), 3.88
(s, 3H, OCH3), 2.00–1.32 (m, 12H, 6 × CH2), 1.20–1.10 (m, 2H, CH2),
0.96–0.88 (m, 2H, CH2), 0.79 (t, J = 7.3 Hz, 3H, CH3) ppm.
Synthesis of Compound X6632—7-(1-
Butylcyclohexyl)-5-methoxy-3-butyl-2H-chromen-
2-one: 4-(1-Butylcyclohexyl)-2-hydroxy-6-
methoxybenzaldehyde (200 mg; 0.69 mmol,
1.00 equiv.), hexanoic acid anhydride (0.56 mL;
517 mg, 2.41 mmol, 3.50 equiv.) and potassium
carbonate (4.8 mg; 270 µmol, 0.05 equiv.) were placed in a microwave
vial and heated at 180 °C for 65 min at 300 W microwave irradiation.
The resulting mixture was allowed to cool to room temperature, poured
onto crushed ice and the pH was adjusted to ≈7 with sodium bicarbon-
ate. The mixture was then extracted with ethyl acetate (3 × 50 mL) and
the combined organic layers were dried over sodium sulfate. Removal of
the volatiles under reduced pressure and purification via flash column
chromatography (CH/EtOAc 100:1) resulted in 210 mg (82%) of an off-
white solid. Rf (CH/EtOAc 50:1): 0.31; MP: 143.8 °C; 1H NMR (400 MHz,
CDCl3): 𝛿 = 7.81 (s, 1H, 4-CH), 6.90–6.86 (m, 1H,HAr), 6.66 (d, J= 1.5Hz,
1H, HAr), 3.92 (s, 3H, OCH3), 2.55 (t, J= 7.7 Hz, 2H, CH2), 2.11–1.94 (m,
2H, CH2), 1.70–1.30 (m, 14H, 7 × CH2), 1.13 (p, J = 7.3 Hz, 2H, CH2),
1.00–0.85 (m, 5H, CH2, CH3), 0.77 (t, J= 7.3 Hz, 3H, CH3) ppm; 13CNMR
(100 MHz, CDCl3): 𝛿 = 162.4 (Cquart., COO), 155.4 (Cquart., CAr), 154.2
(Cquart., CAr), 152.4 (Cquart., CAr), 133.5 (+, 4-CArH), 127.2(Cquart.,
CAr), 108.0 (Cquart., CAr), 107.9 (+, CArH), 103.9 (+, CArH), 55.9 (+,
OCH3), 43.6(Cquart., CCH), 42.3 (–, CH2), 36.5 (–, 2 × CH2), 30.8 (–,
CH2), 30.5 (–, CH2), 26.6 (–, CH2), 25.8 (–, CH2), 23.4 (–, CH2), 22.6 (–, 2
× CH2), 14.1 (+, CH3), 14.0 (+, CH3) ppm. – IR (KBr): 𝜈˜ = 2926 (m), 2854
(w), 1714 (m), 1613 (m), 1570 (w), 1495 (w), 1453 (m), 1413 (m), 1376
(w), 1344 (w), 1291 (w), 1245 (m), 1163 (w), 1104 (m), 1073 (w), 1044
(m), 991 (m), 943 (w), 906 (w), 834 (w), 798 (w), 760 (w), 712 (w), 684
(w), 653 (w), 558 (w), 494 (vw), 429 (vw) cm−1; MS (70 eV, EI):m/z (%) =
370 (96) [M]+, 328 (7), 327 (8), 315 (10), 314 (45), 313 (100) [M – C4H9]+,
274 (6), 271 (5), 259 (5), 246 (10), 245 (54), 233 (19), 203 (7), 202 (11),
189 (5), 81 (7); HRMS (C24H34O3): calc. 370.2502; found 370.2502; El-
emental analysis: C24H34O3: calc. C 77.80; H 9.25; found C 77.78,
H 9.43.
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Synthesis of Compound X6632—7-(1-
Butylcyclohexyl)-5-hydroxy-3-butyl-2H-chromen-
2-one: 7-(1-Butylcyclohexyl)-5-methoxy-3-
butyl-2H-chromen-2-one (116 mg; 356 µmol,
1.00 equiv.) was dissolved in dry dichloromethane
(5 mL). The solution was cooled to −78 °C
and boron tribromide (1.78 mL; 1 m in dichloromethane, 1.78 mmol,
5.00 equiv.) was added dropwise. The mixture was stirred for 30 min at
this temperature and then allowed to warm to room temperature. The re-
action was quenched after 16 h at 0 °C by addition of sodium bicarbonate.
The aqueous layer was extracted with dichloromethane (3 × 15 mL) and
the combined organic layers were washed with brine, dried over sodium
sulfate and the volatiles were removed under reduced pressure. The crude
product was then purified via flash column chromatography (CH/EtOAc
5:1) to give the product as 116 mg (92%) of a white solid. Rf (CH/EtOAc
5:1): 0.43. MP: 154.0 °C; 1H NMR (400 MHz, CDCl3): 𝛿 = 7.89 (s, 1H,
4-CH), 6.83 (d, J = 1.4 Hz, 1H, HAr), 6.73 (d, J = 1.5 Hz, 1H, HAr), 6.54
(s, 1H, OH), 2.70–2.48 (m, 2H, CH2), 2.04–1.93 (m, 2H, CH2), 1.68–1.58
(m, 2H, CH2), 1.57–1.27 (m, 12H, 6 × CH2), 1.17–1.05 (m, 2H, CH2),
0.94 (t, J = 7.3 Hz, 3H, CH3), 0.92–0.83 (m, 2H, CH2), 0.75 (t, J = 7.3 Hz,
3H, CH3) ppm.
13C NMR (100 MHz, CDCl3): 𝛿 = 163.3 (Cquart., COO),
154.3 (Cquart., CAr), 152.7 (Cquart., CAr), 152.2 (Cquart., CAr), 134.3 (+,
4-CArH), 126.8 (Cquart., CAr), 109.1 (+, CArH), 107.5 (+, CArH), 107.1
(Cquart., CAr), 43.8 (–, CH2), 42.0 (Cquart., CCH), 36.4 (–, 2 × CH2),
30.7 (–, CH2), 30.5 (–, CH2), 26.6 (–, CH2), 25.8 (–, CH2), 23.4 (–, CH2),
22.6 (–, CH2), 22.5 (–, 2 × CH2), 14.1 (+, CH3), 14.0 (+, CH3) ppm. – IR
(KBr): 𝜈˜ = 3171 (w), 2925 (w), 2853 (w), 1670 (m), 1613 (m),1573 (w),
1451 (w), 1421 (m), 1345 (w), 1288 (w), 1253 (w), 1185 (w), 1124 (w),
1101 (w), 1066 (w), 939 (w), 862 (w), 842 (w), 782 (w), 745 (w), 728 (w),
608 (vw), 529 (w), 414 (vw) cm−1; MS (70 eV, EI): m/z (%) = 356 (71)
[M]+, 331 (8), 314 (12), 301 (8), 300 (46), 299 (100) [M – C4H9]+, 281
(8), 262 (7), 260 (9); HRMS (C23H32O3): calc. 356.2346; found 356.2347;
Elemental analysis: C23H32O3: calc. C 77.49, H 9.05; found C 77.27,
H 9.09.
Compound Library Screens: To screen the chemical library for com-
pounds with an inhibitory effect on Id1 and Id3 expression, melanoma
cells were simultaneously stimulated with BMP4 (10 ngmL−1, 315–27, Pe-
protech) and treated with the substances at the indicated concentrations
for 24 h. Treatment with CBD served as a reference. DMSO served as a
solvent control. Effects on Id1 and Id3 expression levels were analyzed by
Western blotting.
Statistical Analysis: Statistical analysis was performed usingGraphPad
Prism software. Comparison of two groups was performed using unpaired
two-tailed Student’s t-test. Multiple groups were compared using one-way
ANOVA followed by Tukey’s, Dunnett’s and Fisher’s least significant differ-
ence tests for multiple pairwise comparisons. Tumor initiating cell (TIC)
frequency was analyzed using ELDA software.[84] Tumor growth curves
were compared using nested ANOVA analysis with the help of the statistics
department of the Medical Faculty Mannheim (Dr. Svetlana Hetjens and
Prof. Christel Weiß). Graphs present means with error bars showing stan-
dard error of the mean (SEM). qPCR data were normalized to the mean of
the control condition. The level of statistical significance was defined as *
p < 0.05, ** p < 0.01, *** p < 0.001.
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